Table 6 Summary of clinical trials involving NRF2.
Disease | Medicine | Strategy | Phase | NCT |
|---|---|---|---|---|
HNSCC | Pyrimethamine | Downregulate NRF2 pathway activity | I | NCT05678348 |
PD | Sulphoraphane | Activation of the Keap1/NRF2/ARE pathway | II | NCT05084365 |
Doxorubicin-associated cardiac dysfunction | Sulforaphane | Activation of the NRF2 signaling pathway | [44] | NCT03934905 |
CKD | Sulforaphane | Activation of the NRF2 signaling pathway | II | NCT05797506 |
Acute Coronary Syndrome | Ezetimibe | Activation of the NRF2 signaling pathway | – | NCT04701242 |
Primary Hypercholesterolemia or Mixed Dyslipidemia | Ezetimibe | Activation of the NRF2 signaling pathway | – | NCT04579367 |
Schizophrenia | Luteolin | Inhibit the expression of NRF2 | – | NCT05204407 |
Adrenomyeloneuropathy | Dimethyl Fumarate | Activation of the NRF2 signaling pathway | [47] | NCT06513533 |
Multiple Sclerosis | Dimethyl fumarate | Activation of the NRF2 signaling pathway | IV | NCT05658484 |
Gulf War Illness | Resveratrol | Activation of the NRF2 signaling pathway | – | NCT05377242 |
Advanced or metastatic HR-positive/HER-2-Negative breast cancer | Fulvestrant | Activation of the NRF2 signaling pathway | I | NCT06172322 |
Ataxia | Omaveloxolone | Activation of the NRF2 signaling pathway | I | NCT06054893 |
Rare Chronic Kidney Diseases | Bardoxolone Methyl | Activation of the NRF2 signaling pathway | II | NCT03366337 |
Pre Diabetes | Eriocitrin | Activation of the NRF2 signaling pathway | – | NCT03928249 |
Sickle cell disease | Isoquercitrin | Activation of the NRF2/ARE Pathway | II | NCT04514510 |
Refractory Low-risk MDS | Retinoic Acid | Activate retinoic acid receptors to inhibit NRF2 | I/II | NCT06020833 |
Coronary Artery Disease | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | – | NCT04458116 |
Acute Lymphoblastic Leukemia in Children | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | II | NCT05045443 |
Diabetic Patients With Atherosclerotic Cardiovascular Risk | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | II | NCT05753436 |
Subjective Tinnitus | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | – | NCT04800107 |
Colistin-induced Nephrotoxicity | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | III | NCT05613361 |
Postoperative Adhesion of Bilateral Vocal Cords | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | I/II | NCT05688488 |
Crohn’s Disease | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | II | NCT04713631 |
Childhood Lupus Nephritis | Curcumin | Modification of Keap1 cysteine stabilizes NRF2 expression | II | NCT05714670 |
Obsessive Compulsive Disorder | Pyridoxine | Activation of the NRF2/HO-1 Pathway | – | NCT06244121 |
OC, NSCLC, EC | Brusatol | Specifically inhibiting NRF2 expression | [173] | – |
